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Abstract
The HIV-1 Vpu protein is expressed from a bi-cistronic message late in the viral life cycle. It functions during viral assembly to
maximise infectious virus release by targeting CD4 for proteosomal degradation and counteracting the antiviral protein
tetherin (BST2/CD317). Single genome analysis of vpu repertoires throughout infection in 14 individuals infected with HIV-1
clade B revealed extensive amino acid diversity of the Vpu protein. For the most part, this variation in Vpu increases over the
course of infection and is associated with predicted epitopes of the individual’s MHC class I haplotype, suggesting CD8+ T
cell pressure is the major driver of Vpu sequence diversity within the host. Despite this variability, the Vpu functions of
targeting CD4 and counteracting both physical virus restriction and NF-kB activation by tetherin are rigorously maintained
throughout HIV-1 infection. Only a minority of circulating alleles bear lesions in either of these activities at any given time,
suggesting functional Vpu mutants are heavily selected against even at later stages of infection. Comparison of Vpu
proteins defective for one or several functions reveals novel determinants of CD4 downregulation, counteraction of tetherin
restriction, and inhibition of NF-kB signalling. These data affirm the importance of Vpu functions for in vivo persistence of
HIV-1 within infected individuals, not simply for transmission, and highlight its potential as a target for antiviral therapy.
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Introduction
The HIV-1 genes nef, vpu, vif and vpr are known as accessory genes
and early in vitro studies showed them dispensable for viral replication
in some tissue culture cell lines [1]. In vivo, however, these proteins are
essential for the transmission and persistence of immunodeficiency
viruses. Vpu, in particular, is thought to have been pivotal to the
ability of HIV-1 group M to establish pandemic infection in humans
following transmission from chimpanzees [2,3]. Expressed late in the
viral life cycle, it functions during viral assembly to facilitate efficient
egress of infectious viral particles, through the degradation of CD4 in
the endoplasmic reticulum (ER) and the counteraction of the
interferon-induced antiviral protein tetherin (BST2/CD317) [4,5].
By antagonising tetherin, Vpu also acts to evade innate immune
sensing of budding viral particles by repressing pro-inflammatory
signalling events triggered by tetherin [6–8]. In recent years, Vpu has
been implicated in other immunomodulatory functions, such as the
downregulation of NTB-A/SLAMF6 [9] and poliovirus receptor
(PVR/CD155) [10] to evade NK cell recognition of HIV-1 infected
cells, and the removal of CD1d from the surface of dendritic cells,
inhibiting lipid antigen presentation to NK-T cells [11]. Furthermore,
signature residues in the C-terminus of Vpu are associated with NK
cell escape in KIR2DL2 positive individuals [12].
Vpu is found only in the SIVcpz/HIV-1 lineage of primate
lentiviruses, yet its ability to counteract tetherin and downregulate
CD4 is inconsistent throughout the members of this family. Vpu
proteins from HIV-1 group M tested to date can perform both
functions; the majority of available group N Vpu proteins weakly
counteract tetherin and do not degrade CD4, although show signs
of adapting to human tetherin [13]; while in contrast, group O and
P proteins can degrade CD4 but are fundamentally ineffective at
counteracting tetherin [3,14–16]. The Vpu of the precursor virus,
SIVcpz, can degrade CD4 but is ineffective against both
chimpanzee and human tetherins; in infected chimpanzees, Nef
performs this role by targeting a region of chimpanzee tetherin
deleted in its human orthologue [3,17–19]. Vpu is absent from the
genome of HIV-2, therefore the envelope protein has adapted to the
role of tetherin antagonist in these viruses [20], whilst Nef alone
downregulates CD4. Thus, of all the immunodeficiency viruses able
to infect humans, HIV-1 group M is the only virus group able to
both degrade CD4 in the ER and counteract and ultimately
degrade tetherin, suggesting that the Vpu protein may play a key
role in the transmissibility and pathogenicity of this group, and
potentially its pandemic status [3]. Most characterisation of group
M Vpu thus far conducted has been of the prototypical molecular
clone virus, NL4.3 (reviewed in [4]), on panels of representative
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Vpus from different clades [3,14,15,21], or on bulk-cloned proviral
sequences [22] necessitating an in depth study of natural vpu alleles.
In mice, tetherin activity moderates the replication and
pathogenicity of murine retroviruses [23–25], suggesting it plays
an antiviral role in vivo. Overcoming the physical block to virus
release is one obvious reason that Vpu tetherin antagonism might
be essential for HIV-1 in vivo. However, whether tetherin can block
cell-to-cell transmission of HIV-1, likely to be the predominant
mode of systemic viral spread in lymphoid tissue, is controversial
and cell-type dependent [26–28]. The presence of tetherin at the
virological synapse can, in some circumstances, enhance cell-to-
cell virus spread [27], in agreement with early observations that
Vpu-deleted viruses spread faster in tissue culture [29]. Moreover,
in all studies directly addressing the role of tetherin in cell-to-cell
spread of HIV-1 the effects, either positive or negative, have been
weak. Alternatively, downstream consequences of tetherin restric-
tion in vivo, in particular the recently described pattern recognition
activity of tetherin [6–8], may put extra selective pressure on the
maintenance of Vpu function throughout infection. Tetherin
expression is upregulated on HIV-1 target cells in infected
individuals [30]. Interestingly, sequence changes in Vpu have
been documented in patients co-infected with hepatitis C virus
after treatment with pegylated type-1 interferon [31]. This
prompted us to question whether tetherin antagonism is important
throughout HIV-1 infection in vivo, or whether functional
variability in this attribute is tolerated after the virus has
established a systemic infection.
Using single genome amplification of vpu alleles from infected
individuals and optimised assays for the three major functions of
Vpu, we completed a comprehensive study of Vpu function in
natural HIV-1 infection. Single genome amplification eliminates
sample bias and PCR-based recombination and provides a
representation of the proportion of viral alleles circulating at one
time point, whilst allowing direct progression to tractable
functional assays. In the latter feature, at present, it has an
advantage over deep/next generation sequencing approaches.
Furthermore, deriving vpu sequences from virions rather than cell-
derived provirus is entirely representative of one particular
timepoint, and less likely to contain defective variants in
comparison. The aims of the study were twofold: to comprehen-
sively characterise Vpu sequence variation, immune pressure and
major functions from natural infection; and to inform current
structure-function studies of Vpu by investigating naturally
defective and sub-optimal Vpu proteins.
Results
Vpu sequence repertoire and variation in infected
individuals
Vpu sequences were derived from actively replicating plasma
virus from 14 HIV-1-infected individuals: 5 long-term non-
progressors (LTNP), 5 rapid progressors (RP), and 4 normal
progressors (NP), detailed in Table 1 [32–34]. Patients were
classified as follows, according to standard MACS criteria:
individuals that progressed from seroconversion to AIDS in less
than 5 years were designated RPs; 5–10 years NPs; and greater
than 10 years for LTNPs. All individuals were treatment naı¨ve,
both during and prior to the time of sampling. Up to three
different time points were obtained from each individual, ranging
from seroconversion (0 years) to 10.4 years, with 1–2 year and 3–4
year time points obtained for each individual where possible. To
represent fully the vpu repertoire in each plasma sample and to
maximise the probability of isolating representative minor viral
variants, at least 29 sequences were obtained from each sample,
yielding a total of 851 vpu sequences from all 25 plasma samples
(Table 1). All 851 nucleotide sequences obtained were aligned
and assembled into a maximum likelihood phylogenetic tree
(Figure 1), with vpu sequences from each infected individual
forming a monophyletic group, in accordance with their distinct
origin. Sequences from individuals with different progression rates
to disease did not cluster in proximity to each other, indicating the
lack a direct relationship between a specific vpu sequence and
pathogenic outcome. Individual phylogenetic trees of vpu sequenc-
es from each of the 14 individuals are shown in Figure S1.
The mean intra-patient nucleotide and amino acid diversity for
each individual vpu repertoire is shown in Table 1. vpu sequence
diversity did not correlate with disease progression rates, with
individuals within the groups harbouring a range of sequence
diversity levels (LTNP 1 and 4, for example). As expected, mean
intra-patient nucleotide and amino acid diversity increased over
time in all individuals. There was no correlation between genetic
distance and the number of sequences obtained per sample,
suggesting that the viral repertoire in each sample had been fully
represented (Figure S2). Vpus from LTNP 1 showed the highest
level of genetic diversity, as evident from Figure 1 and Table 1,
however, it should be noted that an extra 10.4 year time point was
analysed from this individual; sequence diversity was comparable
to others from the same progression group at equivalent time
points. We found no indication of APOBEC3-mediated changes
acting on the individual vpu populations (data not shown).
Functional Vpu repertoires from infected individuals
Of the 851 vpu sequences obtained, 456 had unique nucleotide
sequences, and 304 unique amino acid sequences. Of these 304
alleles, five contained readily detectable mutations (i.e. deletions or
frame-shifts), specifically: two contained a premature stop codon
(LTNP2v14_4_51 and LTNP5v22_5_71, resulting in a 6- and 1-
amino acid C-terminal truncation, respectively), one contained a
frame-shift (RP2v16_1_5), and two contained a 1-amino acid N-
terminal deletion (LTNP1v11_4_3 and 5_38). The other 299
Vpus were 81 amino acids in length and thus potentially
functional. Since a single amino acid change can impact on the
function of a protein, all 304 Vpu alleles were cloned and tested in
Author Summary
The accessory protein Vpu, encoded by HIV-1, performs at
least two major roles in the virus life cycle, namely the
degradation of newly synthesized CD4 molecules and the
counteraction of a host antiviral protein, tetherin. These
activities promote the release of infectious viruses from
host cells, and recent evidence suggests that Vpu function
has been crucial for the cross-species transmission of HIV-1
from chimpanzees, and its subsequent pandemic spread in
humans. Here we studied the functional variation in Vpu in
infected individuals. We found that the Vpu amino acid
sequence can be highly variable within an individual, and
that this variation is likely to result from host immune
responses targeting antigens derived from Vpu. However,
despite this variation, Vpu’s major functions are preserved,
with only a minority of circulating alleles showing defects
throughout the course of infection. These data suggest
that defective Vpu proteins are selected against within the
infected individual, implying that Vpu functions are critical
for HIV-1 replication throughout natural infection, not
simply at transmission. Therefore Vpu may represent a
novel target for antiviral therapy to augment current
treatment strategies for HIV/AIDS.
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standard functional assays for CD4 downregulation and tetherin
counteraction. Samples were weighted according to how many
genomes were isolated with a particular amino acid sequence, thus
representing the proportions of functional and non-functional Vpus
present in a given sample (Figure 2). Vpu from the HIV-1 clade B
molecular clone NL4.3 was used as the prototypical Vpu in all
assays, to which the functions of patient-derived Vpu proteins were
compared. Mutant Vpus derived from NL4.3 with defects in
tetherin counteraction (A14L), or both tetherin counteraction and
CD4 downregulation (S52,56A and AW14,22LA) were included in
each assay as negative controls. We also tested Vpus derived from a
panel of HIV-1 clade B transmitted/founder viruses as represen-
tatives of earliest available replicating virus [35]. Assay cut-offs were
determined by the performance of the entire Vpu population, with
the threshold for sub-optimal or defective activity set at one
standard deviation below the mean: for CD4 downregulation this
was 73.7 (mean Vpu function 90.3%, standard deviation 16.6); for
tetherin counteraction this was 81 (mean Vpu function 114%,
standard deviation 33). Based on these criteria, 17 Vpus were
suboptimal/defective for CD4 downregulation, and 41 for tetherin
counteraction.
Interestingly, the founder virus Vpus displayed a spread of
function representative of the 304 patient-derived alleles, with
CH040 Vpu showing sub-optimal activity. There were no
discernible correlations between either of the two Vpu functions
and disease progression groups or time post-seroconversion.
Neither could we detect a correlation between tetherin counter-
activity and viral load; although in six of the eight individuals with
more than one time point, anti-tetherin function did increase with
an increase in viral load (data not shown), but changes were not
significant. CD4 downregulation activity was highly maintained
across all individuals and time points. Vpus from the same
individual had a narrow range of function, with defective Vpus set
apart from the rest of the group, indicative of an intrinsic activity
of each Vpu population. The spread of tetherin counteraction was
broader than that of CD4 downregulation, perhaps due to a more
complex mechanism and more regions of the protein involved in
tetherin downregulation and degradation. In individuals in which
there was a discernable group of suboptimal Vpus, the group was
diminished in number at the later time point (NP 2, NP 3, LTNP
3), suggesting ongoing pressure for Vpu to maintain optimal
function throughout infection.
To assess the impact of single, and thus potentially transitory,
variants, the functional data from Figure 2 were re-plotted after
the removal of all Vpus represented by one single genome,
showing only the variants represented by multiple genomes
Figure 1. In vivo variation of HIV-1 clade B vpu. Unrooted maximum likelihood phylogeny of 851 vpu nucleotide sequences derived from 25
samples from 14 HIV-1-infected individuals. Individuals were classified according to time from seroconversion to progression to AIDS: 5 rapid
progressors (RPs), 4 normal progressors (NPs) and 5 long-term non-progressors (LTNPs) with sequences from each individual coloured and labelled
accordingly. Bootstrap supports (% confidence) are shown at the base of the branch for each individual. Branch lengths indicate the number of
nucleotide substitutions per site.
doi:10.1371/journal.ppat.1003895.g001
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(Figure S3). For the most part, the data remain unaffected, with
only the degree of significance changing over time in some
individuals. Specifically, for CD4 downregulation the decreases
seen for NP 1 and LTNP 5 had higher p values when single
variants were removed, and the NP 2 increase became significant
(p = 0.042). For tetherin counteraction, the increase seen for NP 2
had a higher p value, as did the decreases seen for LTNP 1 and
LTNP 5. For some individuals, removal of single variants lead to
all values for one time point being identical, and in these cases
statistical analyses could not be performed (LTNP 3, LTNP 4).
NL4.3 Vpu – A suboptimal tetherin antagonist?
The majority of our natural Vpu proteins had tetherin counter-
activity superior to that of the NL4.3 Vpu prototype. The ability of
NL4.3 to down-regulate CD4, however, appeared near-optimal
compared to primary Vpu proteins. Direct comparisons between
NL4.3 Vpu and three representative patient-derived Vpus from
each of the three progression groups (RP2v16_2_87, NP2v11_2_1,
and LTNP1v4_1_67), confirmed that NL4.3 performed notably
poorer than typical clade B Vpus in tetherin counteraction
(Figure 3). The three natural Vpus differed in sequence by 7 to 10
amino acids from the sequence of the Consensus B Vpu obtained
from the Los Alamos National Laboratory HIV database. The
expression of the patient-derived Vpus was not greater than that of
NL4.3 by Western blot (Figure 3), and in titration experiments,
up to 100% more infectious virus is released in the presence of the
patient-derived Vpu compared to NL4.3 Vpu. The ability to
downregulate CD4 was optimal for the four proteins (RP2v16_2_87
bearing 101% activity relative to NL4.3, NP2v11_2_1 89%, and
LTNP1v4_1_67 86%), supporting the notion that NL4.3 is inferior
to natural Vpu proteins only in tetherin counteraction. The
superiority of the patient-derived Vpus was further demonstrated
by their suppression of tetherin-mediated NF-kB activation. In
transient tetherin signalling assays, in which tetherin is overex-
pressed to mimic receptor clustering and activate NF-kB [7],
various Vpu constructs were titrated and assessed for their ability to
reduce activation of an NF-kB reporter construct by tetherin. At
25 ng of Vpu the residual tetherin signalling activity in the presence
of RP2v16_2_87, NP2v11_2_1 and LTNP1v4_1_67 was 34, 30
and 30% respectively, compared to 63% in the presence of NL4.3.








4 Genetic distance (substitution/site)
NT AA NT AA
Mean Mean Max
RP 1 1.2 32,280 186 36 18 14 0.007 0.011 0.051
RP 2 1.0 106,070 442 35 22 14 0.032 0.020 0.051
RP 3 2.0 109,736 166 36 28 22 0.018 0.033 0.080
RP 4 2.0 40,403 147 33 21 13 0.013 0.023 0.079
RP 5 1.1 7,095 770 34 13 10 0.007 0.019 0.065
NP 1 1.6 63,265 636 33 17 9 0.010 0.016 0.058
3.5 27,610 498 43 21 13 0.015 0.027 0.078
NP 2 2.0 16,221 513 34 19 14 0.010 0.022 0.063
4.2 62,022 370 33 25 18 0.019 0.029 0.077
NP 3 0 52,367 750 41 12 6 0.005 0.004 0.044
1.6 55,603 553 38 14 10 0.006 0.015 0.060
3.9 266,082 127 33 18 12 0.017 0.030 0.077
NP 4 4.9 303,776 309 30 14 8 0.009 0.015 0.051
LTNP 1 1.1 28,653 429 32 20 18 0.022 0.058 0.168
4.4 106,333 758 32 18 13 0.026 0.060 0.179
10.4 82,071 374 41 27 14 0.039 0.073 0.224
LTNP 2 1.2 8,096 672 31 17 7 0.012 0.008 0.067
3.6 31,766 864 35 21 8 0.020 0.019 0.064
LTNP 3 1.2 6,997 425 29 12 10 0.013 0.035 0.135
4.5 29,229 428 30 18 15 0.029 0.058 0.135
LTNP 4 0 448,694 596 31 4 2 0.001 0.001 0.012
1.1 10,268 276 31 9 5 0.003 0.004 0.034
3.5 12,250 296 33 15 7 0.007 0.008 0.051
LTNP 5 1.1 54,053 986 36 29 20 0.017 0.043 0.181
3.6 30,343 504 31 24 22 0.020 0.045 0.107
1The time point of the plasma sample, in years post-seroconversion.
2Viral RNA copies/ml peripheral blood.
3The total number of vpu sequences obtained per sample by single genome amplification.
4Unique sequences represent the number of alleles per sample after stripping of duplicates.
doi:10.1371/journal.ppat.1003895.t001
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Figure 2. Analysis of CD4 downregulation and tetherin antagonism of 304 natural Vpu alleles. Representatives of all amino acid
sequences obtained through SGA were cloned and tested in standardised assays for the two major functions of Vpu: (A) cell surface CD4
downregulation and (B) tetherin counteraction. The time point of each sample, in years post-seroconversion, is indicated beneath the graph with the
patient identification and progression group. The function of each Vpu is represented relative to the prototypical Vpu from NL4.3, as indicated by a
dashed line at 100%, and the functions of all other Vpus are represented as a percentage thereof. The NL4.3 S52,56A Vpu mutant, defective for both
CD4 downregulation and tetherin counteraction activity, is indicated by a dashed line (at 0% on the CD4 downregulation graph and 13% on the
tetherin counteraction graph). Each symbol represents the average of a minimum of three independent experiments, weighted to represent the
number of sequences obtained per sample with that particular amino acid sequence (allele frequency), to give an overall proportional representation
of function per time point. Means for overall Vpu function for each time point are shown as short horizontal lines. Significant differences between
time points from each individual are indicated by asterisks. Briefly, the assays were performed as follows: (A) HeLa-TZMbl cells were co-transfected
with 100 ng of pCRVI-Vpu or empty vector (EV) plasmid and 100 ng of pCR3.1-eGFP. 24 hours later cell surface CD4 levels were analysed by flow
cytometry. CD4 downregulation was determined by comparing median fluorescent intensities of CD4 in the presence and absence of Vpu, with the
downregulation achieved by NL4.3 Vpu set at 100%. Note that the absolute value of CD4 reduction achieved by NL4.3 was 80%66. (B) 293T cells
were transfected with a fixed dose (50 ng) of pCR3.1-hu-tetherin in combination with 500 ng of NL4.3-del Vpu proviral plasmid and 25 ng of pCRVI-
Vpu. 48 hours later the supernatants are removed from the cells and assayed on Hela-TZMbl cells for the quantity of infectious virus. The 100% line
Preservation of Vpu Function throughout Natural HIV-1 infection
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All patient-derived Vpus almost completely abolished tetherin
signalling at the higher Vpu expression level of 100 ng. Comparison
of the NL4.3 and patient-derived Vpu amino acid sequences
highlights differences in the C-terminal portion of the cytoplasmic
tail, notably in the 2nd alpha-helix where putative trafficking
domains and acidic patches are positioned differently relative to the
conserved phosphorylated serines (Figure 3).
Structure-function analyses of vpu alleles: CD4 vs tetherin
counteraction
When compared for CD4 downregulation and tetherin
counteraction activity, each Vpu had a unique functional profile,
as shown in Figure 4. The vast majority of Vpus were able to
perform both functions (n = 263; 86.5%), yet there were sufficient
numbers of defective proteins to merit investigation of structure-
function relationships. Vpus with levels of activity ranging from
defective to sub-optimal (defined as 0–81% of NL43 activity for
virus release; 0–73.7% for CD4 downregulation) were categorised
according to whether they had defects in tetherin counteraction
only (n = 23; 7.6% of all Vpus), CD4 downregulation only (n = 7;
2.3%), or both (n = 11; 3.6%). Of note, there were more Vpus
defective for tetherin counteraction alone than there were for CD4
downregulation only, and the overall range of function for tetherin
counteraction was broader than that of CD4 downregulation.
Comparing Vpu sequences from different viral isolates in order
to identify regions of functional interest can often be problematic
due to multiple differences between given sequences [14,21].
However, the advantage of using sequences obtained by SGA is
that, in the majority of cases, each defective or suboptimal Vpu has
a functional relative that differs by only one or two amino acids.
Thus, by comparing the sequences of defective Vpus to their
closest functional relatives, and then to the entire Vpu repertoire,
in most cases the amino acid change or changes responsible for the
defect could be identified (Figure 4, Figure S4 and Table S1).
Proteins defective for both CD4 downregulation and tetherin
counteraction (i.e. less than the 81% cutoff for tetherin and 73.7%
for CD4) contained a frame-shift (n = 1), an A19E change in the
transmembrane domain (n = 1), mutations of the highly conserved
regions just prior to (E29K; n = 2) and within (II43,46SL, R49G,
R49T; n = 3) the first alpha-helix, and in the DSGNES hinge
region between the two cytoplasmic alpha helices (D52V,
SN53,55RH, S53N, E58K; n = 4), which contains two phosphor-
ylated serines essential for interactions with the E3 ubiquitin ligase
complex SCFb-TrCP, central to Vpu’s function. Since the
expression of Vpus with defects in both functions could not be
assumed, expression of these proteins was verified by Western blot
analysis, and although variable, all but one Vpu could be detected.
The latter, when compared with known functional proteins from
the same sample, was from a population of Vpus not recognised by
the anti-Vpu antibody used for Western blot analysis (Figure S4).
CD4-specific mutations
Since there were only four Vpus with a defect in CD4
downregulation alone, this presented fewer opportunities for
determining regions specific only to this function. Indeed, in
contrast to tetherin counteraction, there is little consensus in the
literature regarding individual amino acids or motifs in Vpu
specifically governing CD4 downregulation. However, of the three
in which specific changes could be assigned to loss of function,
these mapped to conserved residues in the first alpha helix of the
Vpu cytoplasmic tail (n = 1) and transmembrane region (n = 2),
specifically I17T, V22A and I39L.
One caveat to the CD4-only defects is that, while the tetherin
functions for all of them were more than 81% that of NL4.3, in many
cases they were still suboptimal compared to the better performing
Vpus in the data set. Of note, the transmembrane residues assigned
to CD4 downregulation defects were highly conserved.
Tetherin counteraction-specific mutations
Tetherin-specific functional mutations were tracked to the
transmembrane domain (n = 14), to conserved residues in the first
alpha-helix (E48, n = 2), to the conserved DSGNES hinge region
(n = 3); to the ExxxLV motif (and flanking residues) in the second
alpha-helix (n = 3); and to a conserved tryptophan in the Vpu C
terminus (n = 3); with 2 Vpus with unassignable defects (Figure 4,
Figure S4). At least two regions in Vpu have previously been
assigned specific functions in the context of tetherin counteraction:
in the transmembrane domain, alanines at position 15, 19 and a
tryptophan at position 23 (positions 14, 18 and 22 in NL4.3 for
reference), aligned along one face of the transmembrane helix,
form an interacting surface with the tetherin transmembrane
region [36]; in the second alpha helix of the cytoplasmic domain,
an ExxLV motif, a putative sorting signal, plays a role in
trafficking and degradation of Vpu/tetherin complexes [37]. A
high proportion of the mutations that affected only tetherin
counteraction mapped to an A15 change to a valine or threonine,
(n = 14), and for the most part resulted in a modest reduction in
tetherin counteraction. Since 12.2% (n = 37) of all Vpus contained
a valine at this position, and a further 1.6% (n = 5) a threonine,
and not always immediately conferring a disadvantage in
comparison with NL4.3, the effect at this position is clearly
dependent on context and may potentially weaken the interaction
with tetherin. However, when comparing V15 and T15 Vpus with
matched Vpus from the same infected individual with alanines at
this position (when available), rather than with NL4.3 Vpu, all
demonstrated at least a 50% relative defect in virus release (Table
S1). Interestingly, in two individuals, NP 2 and LTNP 3, V15 or
T15 Vpus make up a large population of sub-optimal Vpus (35.3
and 100% of the 1–2 year time point respectively), with the overall
function of these time points falling at or below the level of NL4.3.
In both cases these are significantly fewer in proportion in the
following time point (using Fisher’s exact test: NP 2 p = 0.043;
LTNP 3 p = 0.0046), indicative of them being selected against, and
the overall function of the subsequent time point is significantly
higher (Figure 2; NP 2, LTNP 3).
In contrast to the variation seen at position 15, only one Vpu
contained a mutation at position 19 (NP1v5_1_80, A19E), leading
to a loss of anti-tetherin function and a severe (2-fold) defect in
CD4 downregulation, whereas W23 was completely conserved,
highlighting its critical role in both major functions of Vpu
[36,38]. Two other mutations in the transmembrane domain led
to a specific loss of anti-tetherin function: I9M and I16E. Whilst
not forming part of the ‘‘alanine face’’ of Vpu, these polar or
charged residues are adjacent and may impact upon accessibility
of the tetherin binding interface.
Interestingly, mutations occurring at the DSGNES b-TrCP
binding site that occurred between the two phosphorylated serines,
N55H (n = 2) and E56G (n = 1), were highly specific and
represents the amount of infectious virus released in the presence of NL4.3, to allow direct comparisons between the CD4 downregulation and
tetherin counteraction assays. 25 ng of pCRVI-Vpu was used as this quantity produced the same amount of Vpu protein as that of the full-length
NL4.3 molecular clone, as determined by Western blot analysis.
doi:10.1371/journal.ppat.1003895.g002
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Figure 3. NL4.3 Vpu as a sub-optimal tetherin antagonist. NL4.3 Vpu and three highly active patient-derived Vpus, RP2v16_2_87, NP2v11_2_1
and LTNP1v4_1_67, were tested at a range of concentrations for their ability to counteract tetherin in a standard virus release assay. 293T cells were
transfected with NL4.3 wild-type (HIV-1 wt) or NL4.3 del Vpu (HIV-1 DVpu), together with 50 ng human tetherin and 0, 5, 10, 25, 50 and 100 ng of
each pCRVI-Vpu. (A) Cell supernatant was filtered and sucrose purified to yield cell-free virions. Cell lysates were analysed for Vpu, Hsp90 (loading
control) and p24 protein expression, and the p24 protein levels in the pelleted virions quantified as a representation of virus released from the cells.
(B) The quantity of infectious virus released into the cell supernatant in the presence of 0, 5, 10, 25, 50 and 100 ng of each of the Vpu proteins was
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deleterious for anti-tetherin activity, but were functional for CD4
downregulation. Mutations at or outside these phosphorylated
serines, as described earlier, had severe effects on both functions
and behaved essentially as the S52,56A mutant used as a
functionally defective control in the function assays. Since b-
TrCP is essential for CD4 downregulation by Vpu [39], these data
suggest that there is a separable element to the function of this
region that is independent of SCF E3 ubiquitin ligase recruitment.
As we had thoroughly examined 304 Vpus for CD4 downreg-
ulation, and tetherin counteraction, we also decided to test those
defective for counteraction of both tetherin functions for their
ability to downregulate cell-surface tetherin expression (Figure
S5). We found the majority of Vpus defective for virus release
maintained the ability to downregulate tetherin, possibly due to
the majority of the mutations tested mapping to the DSGNES,
which has residual function for tetherin downregulation [36,40],
and to the second cytoplasmic helix, previously suggested to have
intermediate impact on internal tetherin sequestration [41].
Further investigation of Vpu proteins containing lesions
in the DSGNES b-TrCP binding motif
The dichotomy of function illustrated in Figure 4 and Figure
S4, wherein observed mutations of the D52, S53, and E58 lead to
a severe defect in both tetherin antagonism and CD4 downreg-
ulation, whilst mutations of N55 and E56 disproportionately
affected tetherin counteraction, warranted further investigation.
The b-TrCP binding consensus sequence is DpSGxxpSE, where
both serines are phosphorylated, and in all b-TrCP substrates
other than Vpu (e.g. IkBa, b-Catenin, CDC25B), the amino acid
adjacent to the glycine is hydrophobic, packing into a hydrophobic
patch in the binding groove of b-TrCP. In Vpu, however, this
residue is a highly conserved hydrophilic asparagine, mutation of
which to histidine results in a dramatic reduction in the ability of
the Vpu to counteract tetherin and promote virus release. We
therefore set out to determine whether this functional defect was
due to a reduced or abolished ability of the Vpu to bind b-TrCP
by performing Vpu and b-TrCP co-immunoprecipitions. Using
the closest functional relative from the same infected individual as
a positive control, we compared the binding of all Vpus that had
mutations in the DSGNES region. As expected, we observed no b-
TrCP binding by Vpus containing mutations of S53, D52, and
E58K. However, we observed a robust binding of b-TrCP by the
N55H and E56G natural Vpu mutants (Figure 5), suggesting an
alternative tetherin-specific defect imposed by these mutations.
Examination of the ability of Vpus to suppress tetherin-
mediated NF-kB signalling
Given the demonstrated superiority of a select few patient-
derived Vpus to suppress tetherin-mediated NF-kB activation
(Figure 3), we next tested all 304 Vpus in order to obtain both a
full picture of signalling suppression in natural Vpu proteins, and
also to discern potential residues in Vpu specifically involved in
this function that have hitherto been uncharacterised. To date,
there have been no reports of regions of Vpu required to
specifically suppress tetherin signalling, although a generalised
suppression of NF-kB activation upon over-expression of NL4.3
Vpu has been linked to the conserved b-TrCP binding site [42].
As with tetherin antagonism, there was a broad range of
signalling-suppressive function, with some time points containing
clusters of inferior Vpu function (Figure 6). Interestingly, in
several individuals, including those from whom a seroconversion
sample was available, signalling suppression was higher in the
early time point and significantly declined over time (Figure 6;
NP2, NP3, LTNP3, LTNP4). In these individuals tetherin
antagonism for virus release increased over time (Figure 2),
indicating a trade off between the two elements of tetherin
counteraction, and that the ability of Vpu to suppress tetherin-
mediated signalling is not wholly determined by the physical
counteraction of tetherin.
Structure-function analyses of vpu alleles: Comparison of
two tetherin counteractivities
Since the Vpu profiles of 14 infected individuals were not
similar when compared for their ability to antagonise tetherin to
promote virus or to suppress signalling, we investigated whether
differences in these two activities could be assigned to specific
amino acid changes not critical for the promotion of virus release.
Taking the same approach as that used to compare tetherin
antagonism and CD4 downregulation, functional profiles of all
304 Vpus were plotted (Figure 7). As is evident from Figure 6,
we observed no correlation between the ability of Vpu to
physically antagonise tetherin and its ability to suppress tetherin
signalling. Mutations that affected both functions were found in
the DSGNES motif, a frameshift, the highly conserved R49 and
E51 in the first alpha helix and A19 in the transmembrane
domain. Interestingly, there were a considerable proportion of
Vpus that were still able to counteract tetherin for virus release,
but had defects in signalling suppression. These mapped to three
conserved residues: G59 and E62 in the second alpha helix of the
cytoplasmic domain, and R45 in the first alpha helix. A cluster of
Vpus had defects that mapped to A50V or -T changes, which
accounted for the suboptimal activity of the majority of Vpus
isolated from NP1 (Figure 6). One more tetherin signalling-
specific defect, I17T, was also defective for CD4 downregulation;
all others were only defective for this particular function (see
Table S1). One Vpu with a major defect in tetherin antagonism,
II43,46SL, was still able to reduce NF-kB activation, and more
modest mutants such as E29K, which were also defective for CD4
downregulation, maintained the ability to reduce tetherin signal-
ling. Minor but common tetherin antagonism defects, A15V or –
T, had no impact on the ability of these Vpus to suppress tetherin
signalling.
The ability of many Vpus to suppress tetherin signalling
independently of their ability to promote virus release prompted us
to investigate whether Vpu possessed a global NF-kB suppression
activity, mediated through the sequestration of b-TrCP, as
previously reported [42,43]. To test this we looked at the effect
of increasing concentrations of various Vpu proteins on the
activation of NF-kB by MAVS, a central adaptor protein in NF-
kB activation pathways triggered by RIG-I-like RNA sensing
receptors.
First we compared the ability of a highly active patient-derived
Vpu (RP2v16_2_87) to counteract tetherin- and MAVS-mediated
NF-kB activation, along with NL4.3 and known mutants thereof
(Figure 8). RP2v16_2_87 Vpu was highly effective in suppressing
assayed on HeLa-TZMbl cells. Error bars represent standard deviation from 3 independent experiments. (C) Inhibition of transient tetherin-mediated
NF-kB activation by Vpu. Fold activation of a luciferase NF-kB reporter gene by expression of 50 ng human tetherin is calculated relative to a GFP
control in the presence of increasing concentrations of NL4.3, RP2v16_2_87, NP2v11_2_1, and LTNP1v4_1_67 Vpu, and results are presented relative
to the mean signal obtained in the absence of Vpu (% max) (D) Amino acid alignment of NL4.3 RP2v16_2_87, NP2v11_2_1, and LTNP1v4_1_67 Vpus.
doi:10.1371/journal.ppat.1003895.g003
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Figure 4. Structure-function analysis of sub-optimal and non-functional Vpus. (A) Functional profiles for the 304 tested Vpus, shown as
tetherin counteraction vs CD4 downregulation, with both functions measured as a percent of NL4.3 Vpu activity (100%, indicated by red arrow; see
Figure 2 for details). Non-functional and sub-optimal Vpus were defined as 0–73.7% of NL4.3 Vpu function for CD4 downregulation, and 0–81% for
tetherin counteraction, determined by one standard deviation below the mean activity of all Vpus tested. Cutoffs are indicated by dark red solid lines.
Vpus were categorised according to whether they were defective for tetherin counteraction (n = 28), CD4 downregulation (n = 4), or both (n = 13),
then compared to their closest functional relatives and to the Vpu population as a whole, to pinpoint the amino acid changes responsible for the
defect. Each defective/sub-optimal Vpu is coloured according to the location of the inactivating mutation, as detailed in the key, and then
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NF-kB activation by both tetherin and MAVS, with an 88% and
94% reduction in signalling by both molecules, respectively, at the
highest concentration tested (Figure 8A). NL4.3, in contrast,
showed a weaker but dose-dependent ability to suppress tetherin
signalling, but was severely defective for the inhibition of MAVS
signalling, with an effect seen only at the highest concentration of
100 ng. The S52,56A NL4.3 mutant, unable to interact with b-
TrCP, had no signalling-suppressive activity against either tetherin
highlighted in (B). (B) A logo plot of the 304 natural Vpu proteins, illustrating the variation at each amino acid position at the population level and
annotated to show the major domains of the Vpu protein. Amino acids with previously known contributions to tetherin counteraction and/or CD4
downregulation are indicated by light grey squares and/or circles above the relevant position, respectively. Sites attributed to loss of function in this
study are coloured according to (A) and indicated by dark grey squares and/or circles for tetherin counteraction and/or CD4 downregulation. Only
the position, rather than the amino acid identity, is shown; for the specific mutations see Figure S4. Note that an unannotated residue does not
necessarily mean it is not essential to either or both of the functions, but rather that this site was invariant. See Figure S4 for further details, and
Table S1 for the complete database of Vpu sequences and functions.
doi:10.1371/journal.ppat.1003895.g004
Figure 5. Further investigation of the b-TrCP binding properties of the N55H and E56G Vpu mutants. (A) We identified seven naturally
defective Vpus with mutations in the DSGNES b-TrCP binding site, or in the adjacent glutamic acid that is essential for the casein kinase II-mediated
phosphorylation of serines 53 and 57. Six of these mutants were tested for their ability to bind b-TrCP in co-immunoprecipitation experiments (B).
Vpu negative (pCRVI), NL4.3 wt (positive control) and NL4.3 S52,56A mutant (negative control) are shown for comparison. In all cases, the mutant Vpu
was compared to its closest functional relative (wt). Vpus are therefore described as the wt Vpu from that individual, plus the position and type of the
DSGNES mutation. 293T cells were co-transfected with pCRVI-Vpu (or EV) and pCR3.1-myc b-TrCP (or GFP) and 48 hours later lysed and
immunoprecipitated with anti-myc antibody.
doi:10.1371/journal.ppat.1003895.g005
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or MAVS, whereas the A14L tetherin binding mutant was able to
partially inhibit NF-kB activation by both proteins at higher
concentrations, consistent with the notion that Vpu mediates a
concentration-dependent generalised inhibition of NF-kB activation
that is independent of its ability to physically counteract tetherin.
We next examined patient-derived Vpus that showed differen-
tial ability to counteract tetherin to promote virus release and to
suppress signalling. Of these, an E29K mutant that was defective
for both tetherin counteraction and CD4 downregulation was
highly active in suppressing both tetherin and MAVS-mediated
NF-kB activation. Conversely, G59R, E62G and A19E mutants
were all impaired, to various degrees, for their ability to suppress
both tetherin- and MAVS-mediated activation of NF-kB.
Positive selection in Vpu sequences from natural
infection
To investigate whether certain amino acid changes were
selected for within a given viral pool, either due to immune
escape or functional advantage, we performed positive selection
analyses on the complete vpu sequence sets from each infected
individual. Overall, the vpu gene was found to be under purifying
selection (mean dN/dS ranging from 0.20 to 0.72 across
individuals), with the identification of several individual amino
acids under positive selection pressure (Figure S6). For the
purposes of the population-level positive selection analysis, only
the part of vpu that does not overlap with the env reading frame
(codons 1–54) was included in the analyses. For the separate
patient analyses, positions that were found to be under positive
selection that fell in the overlap were assessed on an individual
basis (for details see Materials and Methods). Few of the codon
positions under positive selection were common to more than one
individual, although positions in the N-terminus and transmembrane
domain of the protein were frequently selected for (see Table 2,
LTNP 1, 3, 5, NP 1, 2, RP 1 and 2). We found no positively selected
sites associated with patterns of disease progression.
T cell-mediated immune pressure drives the variation
seen in Vpu
Alignments of the amino acid sequences from each plasma
sample show a regional clustering of mutations indicative of
immune pressure, with positions undergoing positive selection
often falling within these areas. We speculated that the regions of
concentrated variation might coincide with T cell epitopes,
previously poorly characterised specifically for Vpu, and that
immune escape was principally driving the variation in the vpu
gene. To ascertain the CD8+ T cell epitope potential of the Vpu
sequences, the majority Vpu sequence from each time point was
entered into a T cell epitope prediction algorithm (IEDB MHC
Class I prediction method version 2009-09-01B), tailored to the
Class I HLA haplotype of the corresponding infected individual
(Table S2).
Overlaying the predicted CD8 T cell epitopes with amino acid
sequence alignments demonstrates an accumulation of mutations
in regions putatively targeted for presentation to CTLs, and often
overlapping with sites under positive selection (Table 2). The co-
localisation of predicted epitopes and positively selected amino
Figure 6. Analysis of tetherin signalling suppression by 304 natural Vpu alleles. As for Figure 2, representatives of all amino acid
sequences obtained through SGA were tested in tetherin signalling suppression assays. The time point of each sample, in years post-seroconversion,
is indicated beneath the graph with the patient identification and progression group. Results are shown as % reduction of maximum tetherin-
mediated NF-kB activation. NL4.3, and the NL4.3 S52,56A Vpu mutant, defective for both CD4 downregulation and tetherin counteraction activity, are
indicated by dashed lines (at 49 and 17%, respectively). Each symbol represents the average of a minimum of three independent experiments,
weighted to represent the allele frequency of each variant, to give an overall proportional representation of function per time point. Means for overall
Vpu function for each time point are shown as short horizontal lines. Significant differences between time points from each individual are indicated
by asterisks. Briefly, the assays were performed as follows: 50 ng of tetherin or empty vector constructs were co-transfected with 50 ng of pCRVI-Vpu
or empty vector, and 10 ng of an NF-kB-dependent firefly luciferase reporter construct and 5 ng of a control renilla luciferase construct. 24 hours
later, cells were lysed and the luciferase activity determined. Results are displayed as % reduction of luciferase activation in the presence of Vpu
relative to the mean maximum activity in the absence of Vpu.
doi:10.1371/journal.ppat.1003895.g006
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Figure 7. Structure-function analysis of Vpus for counteraction of two tetherin activities. (A) As for Figure 4, but functional profiles of
each Vpu is shown according to its ability to counteract tetherin to promote virus release, and to suppress NF-kB activation by tetherin. Tetherin
counteraction (virus release) is measured relative to NL4.3 Vpu (100%), whereas suppression of signalling is presented as % reduction of NF-kB
activation relative to the negative control. Defective/sub-optimal Vpus are defined as 0–81% for tetherin counteraction, and 0–50% for signalling
suppression. Cutoffs are indicated by dark red solid lines. Vpus were categorised according to whether they were defective for tetherin counteraction
for virus release (n = 31), signalling suppression (n = 26), or both (n = 15), then compared to their closest functional relatives and to the Vpu
population as a whole, to deduce the amino acid changes responsible for the defect. Each defective/sub-optimal Vpu is coloured according to the
location of the inactivating mutation, as detailed in the key, and then highlighted in (B). (B) As for Figure 4B, but in contrast, here we have only
indicated residues identified in these analyses involved in tetherin counteraction for virus release (dark grey squares above logo plot), tetherin
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acids explains the apparently random location of such residues.
Furthermore, ordering individuals by genetic distance (mean
nucleotide substitutions/site at time point 1–2 years) illustrates that
those with the most variable Vpu repertoires also have the highest
number of predicted CD8 T cell epitopes, allowing us to speculate
that it is CD8 T cell pressure driving vpu variation, and that
positive selection acting on apparently random positions is an
indication of ongoing diversification within and around putative
epitopes. Interestingly, in LTNP 1, 3 and 5, the individuals with
the highest number of predicted T cell epitopes, a significant drop
in one or both functions can be seen over time.
Of note, one of the positions undergoing positive selection in
LTNP 5 was residue 73, a position previously linked to NK cell
escape in KIR2DL2 individuals [12] (Table 2, Tables S1 and
S2). Upon further investigation we observed at least one change at
this position, or at the associated position 70, in all but two
KIR2DL2 positive individuals (LTNP1, 2, 3 and 5, NP 1 and RP
2); in contrast, these residues were invariant in all KIR2DL2
negative individuals (LTNP 4, NP 2 and 3, RP 3, 4 and 5).
To investigate further the association between predicted T cell
epitopes, immune escape and Vpu variation in more detail, we
selected the vpu repertoire with the highest genetic diversity (LTNP
1), and compared function and sequence changes over time with
predicted T cell epitopes and sites undergoing transient or pervasive
selection (Figure 9). Despite cumulative mutations occurring in
20% of the protein (16 of 80 amino acids, excluding start and stop
codons), pervasive or episodic selection acting at five positions (i.e.
codon positions 2, 4, 7, 9 and 16), and predicted high affinity T cell
epitopes spanning the bulk of its length, every Vpu isolated from this
individual was deemed functional by our classification.
counteraction for signalling suppression (dark grey circles above logo plot), or both, rather than also indicated residues previously identified in the
literature.
doi:10.1371/journal.ppat.1003895.g007
Figure 8. Ability of Vpu to suppress NF-kB activation. (A) NL4.3 Vpu, NL4.3 A14L and S52,56A mutants, and the highly active patient-derived
Vpu RP2v16_2_87 were tested at a range of concentrations for their ability to counteract tetherin-mediated NF-kB activation (left panel) and MAVS-
mediated NF-kB activation (right panel). Transient NF-kB activation assays were performed by transfecting 293 cells with 50 ng pCR3.1 human
tetherin or 10 ng pCR3.1 MAVS alongside 0, 5, 10, 25, 50 and 100 ng of each pCRVI-Vpu. Fold activation of a luciferase NF-kB reporter gene is
calculated relative to a GFP control in the presence of increasing concentrations of Vpu, and results are presented relative to the mean signal
obtained in the absence of Vpu (% max). (B) As for (A), but with patient-derived Vpus with defects in tetherin signalling suppression but not
promotion of virus release (G59R, E62G); patient-derived Vpu with defects in promotion of virus release but not suppression of signalling (E29K); and
patient-derived Vpu with defects in both tetherin signalling suppression and promotion of virus release (A19), all identified in Figure 7.
doi:10.1371/journal.ppat.1003895.g008
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LTNP 3 59 2 0.035 16 16 4-LEIVSIVAL-12 B*4403
5-EIVSIVALV-13 A*2601
61-EELAALVEM-70 B*4403
RP 3 36 1 0.033 5 4-LAILAIVAL-12 B*3501
22-VWSIVLIEY-30 A*2902
RP 4 33 1 0.023 NP




RP 2 35 1 0.020 2 2 NP
RP 5 34 1 0.019 NP
NP 1 76 2 0.016 5 NP
NP 3 112 3 0.015 17-IIAIVVWTI-25 A*2402
68-VEMGHHAPW-76 A*4402
NP 4 30 1 0.015 NP
RP 1 36 1 0.011 NP





LTNP 4 95 3 0.004 NP
All 851 2,4,7,16 2,4,7,15,16,47
Subjects are shown in descending order of those with the highest mean genetic distance, with positive selection occurring at the population level (all sequences),
shown in the bottom row of the table.
1Mean substitutions/site for all time points per subject. Numbers are shown for the 1–2 year time point for each individual, since this is the one time point represented
in all individuals, with the exception of NP 4, for whom the 4.9 year time point was the only one available.
2Sites listed in bold type were picked up by more than one method (FUBAR plus SLAC or FEL); those in standard type were indicated by FUBAR alone.
3Sites indicated by MEME.
4The majority species for each time point was entered into an online T cell epitope prediction tool tailored to the HLA type of the individual. Only epitopes predicted by
more than one method are shown, and in order of where they occur from N- to C-terminus of Vpu. Numbering indicates the amino acid start and end positions. Where
more than one similar epitope was predicted, for example two epitopes overlapping the same region but of 9 and 10 amino acids, the one with the highest predicted
binding affinity is shown. Peptides in bold type have a high predicted affinity (0–50 nM); those in regular type have medium predicted affinity (51–500 nM).
NP =none predicted.
doi:10.1371/journal.ppat.1003895.t002
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Discussion
Using single genome sequencing we have carried out a full
characterisation of the sequence and function of the HIV-1 vpu
gene throughout infection, and demonstrate that the Vpu protein
has a considerable capacity for diversification and adaptation,
consistent with it being one of the most variable regions of the
HIV-1 genome [44]. In the face of predicted CD8 T cell pressure
and significant sequence variation, it is able to maintain function
regardless of disease stage or severity, with no indication of
hierarchy of function.
Vpu function is strictly maintained throughout infection, as
shown by fully functional Vpus obtained from transmitted/
founder viruses, from seroconversion time points and from viruses
isolated more than 10 years post-infection. All three functions
tested – CD4 downregulation, tetherin counteraction for virus
release, and inhibition of tetherin-mediated NF-kB activation –
were maintained, with the vast majority of proteins (96.7%) active
in at least one function. Of the ten Vpu proteins defective for all
three functions, none were found in subsequent time points,
suggesting that seriously defective variants do not persist over time.
More minor defects in a single function did persist over time in
certain individuals, for example those impaired for signalling
suppression seen in NP 1, but the real impact of modest defects in
vivo is difficult to gauge. It is also possible that, for suppression of
signalling, strict maintenance of function is more important at
early stages of infection, and declines with time, as seen most
notably in NP 3.
For tetherin counteraction, maintenance of function reflects
other reports of immunodeficiency viruses responding to the
pressure exerted by tetherin, including the recent characterisation
of a HIV-1 group N Vpu that has evolved to become an efficient
tetherin antagonist [13], the demonstration of acquisition of
tetherin antagonism in the Env proteins of nef-deleted simian
immunodeficiency viruses [45], and the reacquisition of tetherin
counteractivity in Nef following experimental infection of chim-
panzees with HIV-1 [46]. Furthermore, studies of HIV-1/hepatitis
C-co-infected individuals have demonstrated that, following
treatment with pegylated interferon, an increased expression of
tetherin in peripheral CD4+ T cells correlates with a significant
reduction of HIV-1 viral load, with some indication of compen-
satory mutations in Vpu [31]. Selective pressure exerted by
tetherin is indicative of its multiple antiviral effects: not only its
ability to physically prevent the release and spread of virus
particles, its role as a pattern-recognition receptor and potential
enhancer of antigen presentation [47], but also the potential for
enhanced antibody/complement opsonisation and NK cell
recognition that may be downstream consequences of virion
restriction. This is manifest in the observation that populations of
sub-optimal Vpus with specific defects in tetherin counteraction in
early time points, such as the group of Vpus with A15V in NP2
and LTNP 3, are found in significantly lower frequencies at the
subsequent time point, indicative of selection against Vpus with
inferior tetherin binding activity.
Our previous work demonstrates the ability of tetherin to induce
an NF-kB-mediated proinflammatory signal [7], and here we
thoroughly examine the ability of 304 primary Vpus to counteract
tetherin signalling. The suppression of tetherin-mediated NF-kB
activation was observed at a high level across the patient groups
particularly at early time points, with the notable exception of
NP1. However, while the majority of Vpus were superior to NL4.3
Vpu in both functions, there was no direct relationship between
the ability to promote virus release and the ability to suppress
signalling; in some individuals an increase in the former function
over time was mirrored by a decrease in the latter. This prompted
us to investigate whether signalling suppression, particularly by
those Vpus with defects in direct tetherin antagonism, was in part
due to a previously recognised [42,43], and more recently
expanded [48], intrinsic ability of Vpu to globally suppress NF-
kB activation. This ability of Vpu is primarily driven by its binding
of b-TrCP, a component of the SCF E3 ubiquitin ligase complex
that is required for the ubiquitination and degradation of IkB, and
subverted by Vpu for the degradation of its target proteins [49].
Indeed, we confirmed that NL4.3 Vpu was able to suppress NF-kB
activation by both tetherin and MAVS, but only when overex-
pressed, i.e. at levels unlikely to be found in an infected cell. Our
patient-derived Vpus, however, were able to reduce NF-kB
activation even at lower levels of expression, with a complete
ablation of signalling occurring at higher Vpu concentrations,
suggesting that this may indeed be an important role of Vpu in vivo.
Furthermore, the observation of a significant decline in signal-
suppressive function over time in several individuals, in contrast to
the other two functions examined, as well as the high activity
observed in founder virus-derived Vpus, may be indiciative of this
activity being most important in early stages of infection.
In addition to fully characterising natural vpu alleles, the
secondary aim of this study was to identify determinants of the
protein that are required for one or all functions. To the previously
precisely defined regions involved in tetherin antagonism (A15,
A19, W23; E63, L67, V68 [4,36,37]), we contribute I9, A16, E29,
II43,46, E48, R49, E51, N55, E56 and W76. At positions recently
highlighted by McNatt and colleagues to interact with tetherin (I5,
A8, V21, V22, V26, I27, I28), we see variation amongst our
patient-derived Vpus and encountered no changes here that
impacted on tetherin counteractivity. However, an I9M mutation
that was attributed to a serious defect in tetherin antagonism
(Figure 4), is adjacent to a residue proposed to interact with
tetherin [41]. V21 and V22 residues, also indicated as interacting
residues [41], we found had more influence on CD4 downregu-
lation and little impact on tetherin counteractivity.
The N55H and E56G mutations are particularly interesting,
since they occur within the DSGNES motif containing the
phosphorylated serines that mediate interaction with b-TrCP, and
yet these particular changes leave CD4 downregulation largely
intact. While previously suggested to impact on tetherin antago-
nism [50], the lesser impact on CD4 downregulation promted us
to investigate this further. We were able to show that Vpus with
N55H or E56G mutations are still able to bind b-TrCP. Since
other mutations in the DSGxxS diserine motif (e.g. D52V, S53N,
E58K) had severe effects on b-TrCP binding and CD4 downreg-
ulation, this suggests a dual function of this region in accordance
with previous demonstrations that b-TrCP is not strictly required
for tetherin trafficking by Vpu [51]. It is possible that this reflects
an as yet unidentified Vpu co-factor, or involves facilitating access
to either of the two cytoplasmic alpha helices. In this respect, it is
interesting to note that acidic-dileucine motifs, such as the ExxxLV
motif of Vpu, have previously been associated with phosphoryla-
tion in the trafficking of the cation-independent mannose-6-
phosphate receptor [52].
Examination of the ability of 304 different Vpu proteins to
suppress tetherin-mediated NF-kB activation revealed a number
of previously uncharacterised residues important for this function.
Residues that were important for inhibition of tetherin signalling,
but not for the other two tested functions, mapped to G59 and E62
in the second alpha helix, and A50 in the first alpha helix. Vpus
containing G59 and E62 were likewise partially defective in
inhibiting NF-kB activation by MAVS when tested over a range of
concentrations, therefore indicating that this little characterised
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activity of Vpu involves residues in Vpu beyond that of the DSGNES
b-TrCP binding site. Conversely, Vpu proteins that were defective
for tetherin counteraction (e.g. E29K), maintained the ability to
suppress tetherin signalling, and NF-kB activation in general,
presumably through possessing an intact b-TrCP binding site. The
fact that this ability of Vpu involves regions of the protein beyond the
b-TrCP binding site, may indicate that the mechanism of signal
suppression is more complex than the sequestration of b-TrCP.
To the more elusive residues involved in CD4 downregulation,
including V21, S/T24 [38] and L67 [53], we add I17, V22 and I39,
in addition to the E29, I43, I46 and R49 residues also found to affect
tetherin counteraction. We found no mutations in the second alpha
helix that may be attributed to CD4 interaction, as previously
suggested [54], although this may be due to more conservation in this
area and therefore a lack of mutants with potential functional defects.
V22 (V21 in NL4.3 Vpu) has previously been reported to have a mild
effect on CD4 downregulation, as we show here [38]. I17 and I39 are
highly conserved residues, and to our knowledge have not previously
been implicated in CD4 downregulation, although they do fall within
the transmembrane domain and first alpha-helix, two regions other
than the DSGNES b-TrCP binding region previously reported to be
important for CD4 downregulation [4,55].
It is perhaps surprising, considering that few other members of the
immunodeficiency viruses have this capability, that the CD4
degradation activity of virtually all Vpus tested is so strictly
maintained. The reasons for this are unclear; all known immuno-
deficiency viruses possess an activity in Nef that induces the
endocytosis of CD4 from the infected cell surface, with only the
HIV-1 groups M, O and P, and the SIVcpz viral lineage employing
a further Vpu-induced CD4 degradation step in the ER. Yet, there is
little doubt from our data that the degradation of CD4 in the ER is
absolutely required by HIV-1 in vivo, and there is no suggestion that
any redundancy of function exists between Vpu and Nef, or that a
reduction in this function is tolerated over time. HIV-1 envelope
affinity for CD4 is reportedly higher than that of tested SIV envelope
proteins, thus it has been proposed that Vpu is required to effectively
chaperone the Env protein through the ER, thus avoiding this high-
affinity interaction and subsequent loss of Env integrity [56].
The importance of other recently reported functions of Vpu
remains to be explored. Vpu plays a further role in the modulation
of immune recognition of the infected cell through downregulating
the NK cell activating ligand NTB-A [9], and through reducing
the surface expression of PVR and CD1-d [10,11]. Thus far,
studies comparing the effects of Vpu in vitro and in humanised mice
have demonstrated a clear effect of Vpu on CD4 and tetherin,
with modest effects on NTB-A and CD1d [13,57,58]. The
mechanisms also appear to differ, with the serines central to
CD4 downregulation and tetherin counteraction not required for
downregulation of cell surface NTB-A [9]. It will be interesting to
ascertain whether the minority of non-functional alleles isolated in
this study have residual activity against either of the recently
characterised targets, and whether they are present in circulating
virus strains because they modulate the recognition of the infected
cell by NK or NK-T cells. We also see evidence of Vpu’s
immunomodulatory function in signature residues at its C
terminus (amino acids 70 and 73) previously linked to NK cell
escape. Indeed, in KIR2DL2 positive individuals we detect
ongoing variation at these positions; interestingly, this was most
apparent in long-term non-progressors, and in one such individual
we observe positive selection acting at position 73, in accordance
with the amino acid position associated with NK cell escape
characterised by Alter et al [12].
Predicted CD8 T cell pressure coincides with positions of the
protein we detect as being under positive selection. In at least one
individual (LTNP 5) we see evidence of escape from a high affinity
T cell epitope at the later time point. In others, mutations occur in
flanking residues of the peptide, potentially affecting peptide
processing. In the two individuals with the highest variability and
highest predicted T cell pressure (LTNP 1 and 5), we see a
significant reduction of overall tetherin antagonism over time;
however, as discussed above, the levels do not drop below that of
NL4.3 and thus we predict would attain the threshold of activity
required to manage tetherin in vivo.
The demonstration of continuous pressure on the virus to
maintain high levels of Vpu function, and our detailed analysis of
Vpu sequence-function relationship, puts forth strong support for
the development of antiretroviral compounds targeting Vpu,
whilst providing an excellent resource for the future study of
disease-relevant Vpu alleles. In particular, we provide data on the
regions of Vpu common to two or more functions, and those that
appear to be specific to one. We demonstrate that gross defects are
not tolerated, making Vpu a potential target for drug develop-
ment; yet, we stress the importance of assessing multiple
parameters of accessory gene function. In this respect, replication
in culture assays may be misleading as to the potency of a
compound, and may call for validation in new animal model
systems [59]. Furthermore, this study highlights the importance of
using representative primary HIV-1 proteins for the purpose of
vaccinology and drug discovery. Passage in culture, in the absence
of pressure to maintain certain accessory gene functions, can lead
to a lack of potency in several of these proteins, including Vpu.
Thus, there are clear pitfalls that come with using potentially
unrepresentative, albeit historically well characterised, proteins
derived from laboratory-adapted viral strains such as NL4.3.
Materials and Methods
Preparation of RNA and cDNA from clinical samples
Plasma samples were obtained from 14 treatment-naı¨ve
individuals (i.e individuals that had not received treatment either
Figure 9. T cell epitopes and variation. Full analysis of the Vpu repertoire of one infected individual. (A) A phylogenetic tree of vpu
sequences obtained from individual LTNP 1 over 3 different time points: 1.1 (light blue branches), 4.4 (dark blue branches) and 10.4 years post-
seroconversion (purple branches), rooted with both NL4.3 and consensus B vpu sequences. Squares represent unique amino acid sequences, with the
area of the square proportional to the number of Vpus with that specific sequence. The colour of the square is determined by the ability of the Vpu to
counteract tetherin, based on ‘traffic light’ formatting: red being completely unable to counteract tetherin (0%), yellow having intermediate activity
(75%), and green being highly active (150%). Note that in this individual most Vpu proteins had more than intermediate activity, therefore most
squares are shades of green, with the darker the green the more active the protein. Branch support is indicated by one (.70%) or two (.90%)
asterisks. Branch length represents the number of nucleotide substitutions per site. (B) An alignment of all of the unique amino acid sequences
obtained from LTNP 1 and shown in (A), ordered from top to bottom according to their phylogenetic relationship. Sequence 1, to which all
subsequent Vpus are compared, is that closest to the root of the tree shown in (A). The position of each sequence in the tree is indicated on the left
of the alignment. Anti-tetherin activity is indicated by colour, as shown in (A). Substitutions from the ancestral sequence are highlighted in the
alignment in purple, with the tally of cumulative mutations indicated on the right of the alignment. Predicted high affinity (0–50 nM) T cell epitopes,
tailored to the HLA haplotype of the infected individual, are indicated above the alignment. Positions undergoing positive selection are denoted by a
‘‘P’’ above the alignment, with residues undergoing episodic selection (indicative of immune pressure) indicated by ‘‘E’’.
doi:10.1371/journal.ppat.1003895.g009
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during or prior to sampling) enrolled at the Chicago Clinical
Research Site for the Multicentre AIDS Cohort Study (MACS).
HIV-1 disease progression was defined by time to AIDS and
included 5 long-term non-progressors (defined as .10 years from
seroconversion to onset of AIDS), 4 normal progressors (5–9 years
to onset of AIDS), and 5 rapid progressors (,5 years to onset of
AIDS) [32–34]. Where possible, a 1–2 year and 3–4 year post-
infection time point was obtained per individual. Progression
status was assigned retrospectively, as standard in the MACS. For
the RPs in this study, early disease progression precluded the
availability of a 3–4 year time point. For NP 3 and LTNP 4,
additional seroconversion time point (0 years) was also analysed,
and for LTNP 1 a 10.4-year time point.
The volume of plasma equivalent to 10,000 copies of viral RNA
(based on standard clinical viral load measurements) was first
centrifuged to remove cellular debris (5,4006g at 4uC for 10 mins),
then the virions were pelleted (25,0006g at 4uC for 1 hour).
Viruses derived from blood samples collected in heparin were then
heparinase treated to avoid inhibition of downstream enzymatic
processes. RNA isolated from the virion pellets was then
transferred to standard reverse transcription reactions (Invitrogen
Superscript III), using Vpu-specific outer reverse primer (see SGA
section below), according to manufacturer’s instructions.
Single genome amplification (SGA)
Single genome amplification techniques were based on methods
described in Palmer et al. [60] Nested PCR primers were designed
to conserved regions in the tat/rev first exon and the env gene
according to sequences derived form the Los Alamos National
Laboratory HIV Sequence Database (forward EK5846-5869 59-
CCT AGA CTA GAG CCC TGG AAG CAT-39; reverse
EK6473-6453 59-TTC TTG TGG GTT GGG GTC TGT-39),
with the inner primers containing standard sequencing primer
sequences T7 and M13 (forward EK5972-5990 59-TAA TAC
GAC TCA CTA TAG GCA GGA AGA AGC GGA GAC A-39;
reverse EK6848-6330 59-CAG GAA ACA GCT ATG ACC CCA
TAA TAG ACT GTG AC-39), numbered according to the HXB2
molecular clone. Viral cDNA was serially three-fold diluted from
1:5 to 1:405 and used as a template for multiple PCRs. We first
performed 12–24 reactions at the highest dilution, and the number
of positive reactions was used to calculate the cDNA dilution at
which approximately 30% would be positive as predicted by the
Poisson distribution. We then performed 92 PCRs at this modified
dilution, and reactions yielding a product were directly sequenced
with T7 and M13 primers (MWG Eurofins, Germany). Chro-
matograms were carefully examined for the presence of double or
multiple peaks.
Phylogenetic analyses
For each patient, complete vpu gene sequences were manually
aligned with the software Se-Al version 2.0a11 [61]. Maximum
likelihood phylogenies were reconstructed under the General
Time reversible (GTR) model of nucleotide substitution, with
gamma-distributed rate heterogeneity, using RaxMLGUI version
1.2 [62]. Robustness of the tree topologies was assessed by non-
parametric bootstrap testing, with 1000 replicates, also performed
with RaxmlGUI. Trees were edited using the software FigTree
version 1.3.1 [63]. A maximum likelihood phylogeny containing
sequences from all patients was also reconstructed following the
same procedure.
Intra-host pairwise genetic distances were calculated using the
phylogenetic package HyPhy version 2.1.2 [64]. For each
alignment, nucleotide and amino acid substitution matrices were
estimated under the GTR and Whelan & Goldman models
respectively.
Codon-specific selection analyses were conducted via the
HyPhy webserver DataMonkey [65]. Three different methods
were used to identify vpu sites evolving under constant adaptive
pressure: Single Likelihood Ancestor Counting (SLAC), Fixed
Effects Likelihood (FEL) and Fast Unbiased Bayesian Approxi-
mation (FUBAR). For each patient, estimations were conducted
under the best fitting model of nucleotide substitution, as selected
by the model selection procedure implemented in DataMonkey.
Sites showing evidence for positive selection by more than one
method at the p,0.05 (SLAC and FEL) or posterior probability
.0.95 (FUBAR) significance level were included in the study. In
addition, the Mixed Effects Model of Evolution (MEME) method
was used to identify sites subjected to episodic selective pressures
(posterior probability .0.95). Sequences were screened for
recombination prior to analyses, using the Single Breakpoint
Recombination (SBR) and Genetic Algorithms for Recombination
Detection (GARD) methods implemented in DataMonkey. No
recombination breakpoint was found at the p,0.05 significance
level. Codons found to be under positive selection that were
located in the region of vpu that overlaps with the env open reading
frame (codons 55–81), were assessed on an individual basis as
follows: a non-synonymous change in vpu that was synonymous in
env was scored as positive; a non-synonymous change in both genes
was impossible to reliably determine which gene the selection was
acting on, therefore these cases were excluded from the results.
To identify codon-specific selective pressure on the vpu gene at
the population level, the above-mentioned procedure was repeated
on an alignment containing the unique nucleotide sequences from
all patients (n = 443). For population-level selective pressure, data
are presented pertaining only to the region of the vpu gene that
does not overlap with the env open reading frame (codons 1–55).
Vpu cloning and expression
Vpu repertoires from each time point were stripped of
duplicates, and all unique amino acid sequences from each sample
were re-amplified using the inner forward and revers primers
described above modified with EcoR1 and Not1 restriction sites
respectively. Products from these reactions were then cloned into
an Rev-dependent HIV-1-based expression vector, pCRVI [20],
to obviate the need to codon optimise the Vpu sequence [66]. The
resultant plasmids were then re-sequenced, to ensure that no
mutations were introduced into the vpu genes during the cloning
process.
Tetherin counteraction (virus release) assay
HEK293T cells were seeded at 1.56105 per well of a 24-well
plate the day before transfection. Cells were co-transfected with
500 ng NL4.3delVpu provirus plasmid, or NL4.3 wild-type
plasmid as a control, plus 50 ng pCR3.1-human tetherin plasmid,
or pCR3.1 empty vector as a control, plus a standard input of
25 ng of pCRVI-Vpu, or pCRVI empty vector as a control. In the
case of titration experiments, 5, 10, 25, 50 and 100 ng of pCRVI-
Vpu were used in each assay, with the total plasmid quantity kept
constant by the addition of pCRVI empty vector plasmid to a total
quantity of 100 ng. Cell culture medium was removed 14 hours
after transfection, and replaced with 600 ml per well. 48 hours
after transfection, viral supernatants and cell lysates were
harvested, and infectious virus released determined by standard
HeLa-TZMbl assay and virus particle release determined by
Western blot. Each Vpu was tested in a minimum of three
independent experiments, and results were compared between
experiments by setting the level of infectious virus released in the
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presence of NL4.3delVpu virus plus pCRVI-NL4.3 Vpu as 100%,
and expressing the activity of the patient-derived Vpus as a
percentage thereof. NL4.3 Vpu constructs with defects specifically
in tetherin antagonism (A14L), or tetherin antagonism plus CD4
downregulation (S52,56A and A14L/W22A) were included in all
assays as negative controls.
CD4 and tetherin downregulation assay
HeLa-TZMbl cells were seeded at 86104 cells per well of a 24-
well plate the day before transfection. Cells were co-transfected
with 150 ng pCR3.1-GFP or empty vector control, and 100 ng
pCRVI-Vpu or empty vector control. 24 hours after infection,
cells were harvested and stained for cell surface molecule
expression using a mouse anti-human CD4 monoclonal antibody
directly conjugated to allophycocyanin (APC; clone RPA-T4; BD
Biosciences), or a mouse anti-human tetherin monoclonal
antibody (clone 3H4, Novus Biologicals) followed by an IgG2a
specific anti-mouse-Alexa Fluor 633 secondary antibody (Life
Technologies). Cells were then analysed for CD4 or tetherin and
GFP levels using a FACSCalibur flow cytometer (Becton
Dickinson) and FlowJo software (TreeStar Inc, Oregon, USA).
Cells expressing high levels of GFP were gated and CD4/tetherin
levels were determined as the median fluorescent intensities.
Absolute downregulation levels were calculated as the percentage
reduction of CD4/tetherin cell surface expression (median
fluorescent intensity) in the presence of Vpu compared to in the
absence of Vpu (empty vector transfection). For the purposes of
comparison with the tetherin counteraction assay, the absolute
level of CD4/tetherin downregulation obtained in the presence of
NL4.3 Vpu was normalised to 100%, and therefore the CD4/
tetherin downregulation by all other Vpus expressed as a
percentage thereof. (Note that the absolute CD4 downregulation
in the presence of NL4.3 Vpu was 80+/26%).
Signalling suppression assay
HEK293 cells were seeded at 1.26105 per well of a 24-well
plate the day before transfection. Cells were co-transfected with
10 ng 36kB-pConA-FLuc 50 and 5 ng pCMV-RLuc reporter
constructs, plus pCR3.1-human tetherin plasmid, or 3.1-MAVS/
IPS1/Cardif, or GFP plasmid as a control, and 50 ng of pCRVI-
Vpu or pCRVI empty vector as a control. 24 hours after
transfection cells are harvested and luciferase activity measured
with the Dual Luciferase Reporter Assay System (Promega).
Luciferase signals were normalised, and fold NF-kB activation
calculated in the absence of Vpu expression. In the case of titration
experiments, 5, 10, 20, 50 and 100 ng of pCRVI-Vpu were used
in each assay, with the total plasmid quantity kept constant by the
addition of pCRVI empty vector plasmid to a total quantity of
100 ng.
Expression of defective Vpu proteins
All Vpus classified as defective or suboptimal for both CD4
downregulation and tetherin counteraction (i.e. 0–75% that of
NL4.3 Vpu activity) were tested for expression in 293T cells by
Western blot analysis using a polyclonal rabbit anti-Vpu antibody
[67] kindly provided by Klaus Strebel through the NIH AIDS
Reagent Program. Since this antibody is specific for the C-
terminal region of NL4.3 Vpu, and the patient-derived Vpus differ
considerably in amino acid sequence from NL4.3 Vpu, expression
of each defective/suboptimal Vpu was compared to that of its
nearest functional relative from the same infected individual.
Defective/suboptimal Vpus that showed low or no expression
were re-transformed, re-purified and then re-sequenced to ensure
the quality of the plasmid preparation, and in all cases the
expression levels before and after this process were comparable.
Defects were therefore deemed to be due to natural expression
defects or instability of the expressed protein.
Immunoprecipitations
293T cells were co-transfected with 600 ng of pCR3.1-b-TrCP2
myc or GFP and 600 ng of pCRVI-Vpu or EV. 48 hours after
transfection, cross-linking immunoprecipitations were performed
[68]. Briefly, cross-linking was preformed on harvested cells using
0.05% HCHO, then lysed in 150 mM NaCl, 10 mM Hepes (pH),
6 mM MgCl2, 2 mM DTT, 10% glycerol, 0.5% NP40, 200 mM
sodium orthvanadate and protease inhibitor cocktail. Cleared
lysates were immunoprecipitated with mouse anti-myc monoclo-
nal antibody (clone 9E10, Covance) and protein G agarose beads
(Invitrogen). Cross-linking was reversed with 10 mM EDTA,
5 mM DTT and 1% SDS, and lysates and immunoprecipates
were analysed by Western blot using mouse anti-myc and rabbit
anti-Vpu antibodies.
Statistics
Unpaired two-tailed T tests were used to determine significant
differences between samples for the CD4 downregulation
(Figure 2A), tetherin counteraction (Figure 2B) and suppression
of tetherin activation of NF-kB (Figure 6). A two-tailed Fisher’s
exact test was used to determine whether Vpus containing a
threonine or valine at position 15 instead of alanine decreased over
time in certain individuals. Levels of significance were determined
as follows: *** p,0.001, ** p,0.01, *p,0.05, ns p.0.05.
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Supporting Information
Figure S1 Phylogenetic trees of vpu sequences obtained
from 14 HIV-1-infected individuals. Maximum likelihood
phylogenies of vpu nucleotide sequences derived from 14 HIV-1-
infected individuals. Bootstrap supports (% confidence) are shown
at the base of the branch for each individual. Branch lengths
indicate the number of nucleotide substitutions per site. The trees
are rooted against NL4.3 and consensus B vpu sequences (black
branches). Where multiple time points were available from one
individual, earliest samples are depicted in turquoise circles; dark
blue squares for intermediate time points; and purple stars for the
later time point. (A) LTNP 1 (1.1, 4.4 and 10.4 yrs); (B) LTNP 2
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(1.8 and 4.2 yrs); (C) LTNP 3 (1.2 and 4.5 yrs); (D) LTNP 4 (0, 1.1
and 3.5 yrs); (E) LTNP 5 (1.1 and 3.6 yrs); (F) NP 1 (1.6 and
3.5 yrs); (G) NP 2 (2 and 4.2 yrs); (H) NP 3 (0, 1.6 and 3.9 yrs); (I)
NP 4 (4.9 yrs); (J) RP 1 (1.2 yrs); (K) RP 2 (1.0 yrs); (L) RP 3
(2.0 yrs); (M) RP 4 (2.0 yrs); and (N) RP 5 (1.1 yrs). The
phylogenies of LTNP 3 and NP 1 were reconstructed after
exclusion from the alignment of polymorphic residues showing
evidence of reversion to wild type over time (codon positions 37
and 22 for LTNP 3 and NP 1 respectively), causing the artefactual
clustering of late sequences closer to the outgroups than to those
from the earlier time points.
(PDF)
Figure S2 Genetic distance vs sequence number. Mean
and maximum genetic distance values (GD; nucleotide substi-
tutions per site) for each clinical sample used in this study were
plotted against the total number of vpu sequences obtained per
sample, as shown in Table 1. R2 values are shown next to the
slopes. A lack of correlation between the parameters is
consistent with the vpu sampling number being sufficient to
represent the viral population in peripheral blood at a given
time point.
(TIF)
Figure S3 CD4 downregulation and tetherin counterac-
tion of only multiple variants. Data from Figure 2 for CD4
downregulation (A) and tetherin counteraction (B) were re-plotted
after the removal of all Vpus derived from a single genome to
assess the impact of potentially transient variants on the outcome
of the analyses. See legend from Figure 2 for details. Differences
in function between time points were re-analysed for significance;
in some cases, removal of single variants lead to all values for one
time point being identical, and in these cases statistical analyses
could not be applied (n/a; LTNP 3, LTNP 4).
(TIF)
Figure S4 Detailed annotation of defective Vpu vari-
ants. (A) Defective and suboptimal Vpus categorised according to
the location in which the mutations responsible for their defects
occur, with the specific amino acid change indicated for each
allele. (B) Vpus with defects in both functions were checked for
expression by Western blot analysis. The only construct from
which no Vpu expression could be detected is marked with an
asterisk, but in this case closely-related fully functional Vpus could
not be detected either, suggesting a lack of antibody-reactivity.
(TIF)
Figure S5 Ability of 30 patient-derived Vpus to down-
regulate cell surface tetherin levels. NL4.3 Vpu and three
mutants thereof (S52,56A; A14L; and AW14,22LA), 28 patient-
derived Vpus with various severe to minor defects in tetherin
antagonism (see Figure 4 and Figure S4), a fully functional
patient-derived Vpu (pos), and a founder virus-derived Vpu
(WITO), were tested for their ability to downregulate tetherin cell-
surface expression. TZMbl cells were transfected with 300 ng
pCRVI-Vpu or EV and 300 ng pCR3.1-eGFP. 48 hours later cell
surface tetherin levels were determined by flow cytometry. Fold
tetherin downregulation was determined by comparing median
fluorescent intensities of tetherin in the presence and absence of
Vpu. Top panel: examples of FACS plots for EV, NL4.3 wt,
S52,56A, A14L and AW14,22LA, and positive control Vpu
LTNP1v4_1_67. Bottom panel: fold reduction of tetherin cell
surface expression. Error bars represent standard deviation from
the mean of 3 independent experiments.
(TIF)
Figure S6 Positive/purifying selection acting on the vpu
gene at the population level. All 851 sequences obtained were
stripped of duplicates and analysed for codon-specific selective
pressure at the population level. Three independent methods
were used (SLAC, FEL and FUBAR) and FUBAR estimates of
dN-dS are represented for each of the 81 codons across the vpu
gene. Sites undergoing significant positive and negative selection
are highlighted in red and blue respectively (posterior probablility
.0.95).
(TIF)
Table S1 Complete sequence-function data of 304
natural Vpu proteins. The amino acid sequences, CD4
downregulation activity and tetherin counter-activity of 304 vpu
alleles isolated from 14 HIV-1-infected individuals are shown in
Excel format. Filters have been applied to each column so that the
sequences can be ordered or selected by function, individual,
progression group, or by particular residues at each position. Vpus
are named according to (i) the individual from whom they were
derived (e.g. RP 1), (ii) the visit to the clinic when the sample was
obtained, and (iii) the sequence ID. The frequency of occurrence
of each particular allele in a given time point is indicated by the
column headed ‘‘N = ’’. Function is expressed as a percentage of
that of NL4.3 Vpu, with traffic light formatting: red indicating no
activity, yellow indicating intermediate, and green indicating
highly active, with a continuous spectra of colour across these
definitions. NL4.3 and Consensus B Vpu sequences are given at
the top of the table for comparison, along with amino acid position
and a schematic of the different regions of the protein
(TM = transmembrane domain, H1 and H2 = first and second
alpha helices, respectively. Amino acids in the patient-derived
sequences that differ from that of Consensus B Vpu are
highlighted in blue. Amino acids that have been assigned to loss-
of-function of a given Vpu (as detailed in the text) are highlighted
in red.
(XLSX)
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